| A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT05219721) | Chunrui Li | 2022-03-17 |
| Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation (NCT05054478) | Assistance Publique - Hôpitaux de Paris | 2021-10-01 |
| A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH (NCT05283993) | Peking University First Hospital | 2021-07-01 |
| Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry (NCT05556928) | University of Alabama at Birmingham | 2020-07-21 |
| Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia (NCT03591744) | City of Hope Medical Center | 2018-10-25 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT03389347) | University of Washington | 2018-02-14 |
| Registry for Adults With Plasma Cell Disorders (PCD's) (NCT03717844) | UNC Lineberger Comprehensive Cancer Center | 2018-02-09 |
| a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients (NCT04008888) | Institute of Hematology & Blood Diseases Hospital, China | 2018-01-05 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma (NCT02506959) | M.D. Anderson Cancer Center | 2015-09-14 |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma (NCT02504359) | OHSU Knight Cancer Institute | 2015-07-20 |
| Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma (NCT02315157) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2014-06-01 |
| Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01729091) | M.D. Anderson Cancer Center | 2013-06-10 |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia (NCT01372540) | M.D. Anderson Cancer Center | 2012-02-24 |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) (NCT01435720) | Senesco Technologies, Inc. | 2011-09-01 |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357) | City of Hope Medical Center | 2011-01-28 |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia (NCT01008462) | Fred Hutchinson Cancer Center | 2010-03-18 |
| A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma (NCT00821249) | Pfizer | 2009-01-01 |
| Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen (NCT00615589) | University of Michigan Rogel Cancer Center | 2008-02-01 |
| Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants (NCT00307086) | H. Lee Moffitt Cancer Center and Research Institute | 2005-06-01 |
| Expanded Access to Venetoclax (NCT03123029) | AbbVie | |